Reading device, drug delivery device and drug delivery device in combination with a reading device

ABSTRACT

The present disclosure provides a reading device adapted to read-out infrared readable data provided by a covered part of a movable component of a drug delivery device, wherein the reading device comprises at least one electromagnetic radiation source configured to emit infrared radiation and adapted to illuminate the infrared readable data on the covered part; at least one optical sensor unit configured to detect infrared radiation reflected from the covered part of the movable component; and at least one processing unit configured to determine a data value of the infrared readable data as a function of the detected reflected infrared radiation. The disclosure further provides a drug delivery device and a drug delivery device in combination with the reading device.

CROSS REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent applicationSer. No. 16/330,259, filed on Mar. 4, 2019, which is the national stageentry of International Patent Application No. PCT/EP2017/072578, filedon Sep. 8, 2017, and claims priority to Application No. EP 16188184.2,filed on Sep. 9, 2016, the entire disclosures of which are incorporatedherein by reference.

TECHNICAL FIELD

This disclosure generally relates to a reading device. The disclosurefurther relates to a drug delivery device and to a drug delivery devicein combination with a reading device.

BACKGROUND

Administering an injection is a process which presents a number of risksand challenges for users and healthcare professionals, both mental andphysical. Such injections can be performed by using injection devices,which are applied either by medical personnel or by patients themselves.

SUMMARY

Pen type drug delivery devices and autoinjectors have been designed anddeveloped to perform regular injections by persons without formalmedical training. This is increasingly common among patients havingdiabetes where self-treatment enables such patients to conduct effectivemanagement of their disease. For example, an insulin dose needed to beinjected can be manually selected by turning a dosage knob arranged on apen device and observing the actual dose from an aperture or dose windowof the pen device. The dose is then injected by inserting the needleinto a suited skin portion and pressing an injection button of the pendevice. To be able to monitor the insulin injection, in particular toprevent false handling of the pen device or the autoinjector or to keeptrack of the doses that are already applied, it is desirable to measureinformation related to a condition and/or use of a drug delivery device,such as a selected dose.

Described herein is an improved reading device, an improved drugdelivery device and a drug delivery device in combination with such areading device.

A reading device, a drug delivery device, and a drug delivery device incombination with a reading device are described in the claims. Exemplaryembodiments are provided in the dependent claims.

BRIEF DESCRIPTION OF THE DRAWINGS

The present disclosure will become more fully understood from thedetailed description given below and the accompanying drawings, whichare given by way of illustration only, and do not limit the presentdisclosure.

FIG. 1 is a schematic section of a cut-out of an exemplary embodiment ofa drug delivery device comprising a movable component, according to theembodiments of the present disclosure.

FIG. 2 is a schematic perspective view of a cut-out of an exemplaryembodiment of a drug delivery device and a reading device comprising anelectromagnetic radiation source and an optical sensor unit, accordingto the embodiments of the present disclosure.

FIG. 3 is a schematic view of two pixel patterns each comprising tworows of four pixel and a machine or infrared readable data representedby a binary code, according to the embodiments of the presentdisclosure.

FIG. 4 is a schematic view of a visual data represented by a singledigit of a number and an infrared readable data assigned to the visualdata, according to the embodiments of the present disclosure.

FIG. 5 is a schematic view of a visual data represented by three digitsand an assigned infrared readable data, according to the embodiments ofthe present disclosure.

FIG. 6 is a schematic perspective view of a cut-out of an exemplaryembodiment of a drug delivery device and a reading device, according tothe embodiments of the present disclosure.

FIG. 7 is a schematic cut-out view of a cut-out of an alternativeexemplary embodiment of the drug delivery device and the reading device,according to the embodiments of the present disclosure.

FIG. 8 is a circuit diagram of an electromagnetic radiation source of areading device, according to the embodiments of the present disclosure.

FIG. 9 is a circuit diagram of an optical sensor unit of a readingdevice, according to the embodiments of the present disclosure.

FIG. 10 is a block diagram representing a reading device and a drugdelivery device, according to the embodiments of the present disclosure.

Corresponding parts are marked with the same reference symbols in allfigures.

DETAILED DESCRIPTION

The disclosure relates to a reading device that is adapted to read-outinfrared readable data that is provided on a movable component of a drugdelivery device. The reading device comprises at least oneelectromagnetic radiation source configured to illuminate a covered partof the movable component, at least one optical sensor unit configured toemit infrared radiation and adapted to detect infrared radiationreflected from the covered part of the movable component and at leastone processing unit that is configured to determine a value as afunction of the detected reflected infrared radiation.

The reading device allows measuring information related to a conditionand/or use of a drug delivery device, such as a selected dose. Forinstance, a patient having diabetes needs to select a specific dose ofinsulin required for achieving a good blood glucose level. A patientperforming self-administration of insulin will commonly need to select adose of insulin between 1 and 80 International Units. The providedreading device allows reading out infrared readable data invisible to auser without the requirement of an additional window or aperture in thedrug delivery device. Furthermore, the reading device enables indicatinga selected dose as well as recording dosage history. The dosage historymay be an important factor in calculating future doses.

The reading device may optionally comprise a transmitter to transmit thedata and/or the data value as read from the drug delivery device toanother device, e.g. transmit the data wirelessly, for example via radioor Bluetooth® connection, to a mobile phone or a walk-by device or aremote terminal.

According to a further embodiment the reading device is configured as anintegral component of the drug delivery device. Alternatively thereading device may be supplemental to the drug delivery device. Forexample, the reading device may be configured to be attached to the drugdelivery device, for example releasably or alternatively irreleasably.

In particular, the at least one electromagnetic radiation source may beconfigured as a light emitting diode (LED) emitting infrared radiation.Infrared radiation emitting diodes are powerful, economical and durablecomponents at least until a wavelength range of 900 nm. Furthermore,emitting infrared radiation allows transmitting through the opaque partof the case of the drug delivery device and thus reading out theinfrared readable data that is covered by the case and/or by additionallayers applied onto the movable component.

To improve the signal quality, the at least one electromagneticradiation source may be coupled to a power source configured to supplypulsed electric current. In particular, the power source is configuredto supply a pulsed electric current high enough for the at least oneelectromagnetic radiation source to emit infrared radiation with anintensity significantly higher than extraneous light. This enables aneasy evaluation of the measured electromagnetic radiation by theprocessing unit, e.g., by using tresholding. For evaluation, theprocessing unit may be alternatively or additionally coupled to orprovided with a pulse width modulation generator or with a pseudo-randomsignal generator.

For detecting electromagnetic radiation, in particular infraredradiation, emitted by the at least one electromagnetic radiation sourceand reflected from a surface of the movable component, the readingdevice comprises the at least one optical sensor unit, which maycomprise a number of photodiodes, e. g. silicon photodiodes, fordetection. Alternatively, the at least one optical sensor unit maycomprise an optical waveguide. The reading device may further comprise aprocessing unit for analysing the signals of the optical sensor unit.

The analysis could provide a decoding of an encoded infrared readablesignal or a signal strength interpretation.

In an exemplary embodiment, the at least one electromagnetic radiationsource is arranged adjacent to the at least one optical sensor unit suchthat the at least one optical sensor unit is capable to detect infraredradiation that is emitted by the at least one electromagnetic radiationsource and reflected by the covered and invisible part of the movablecomponent.

In an exemplary embodiment, the at least one optical sensor unitcomprises a number of photodiodes, wherein the at least oneelectromagnetic radiation source is arranged adjacent to the number ofphotodiodes. In particular, the at least one electromagnetic radiationsource may be arranged horizontally side-by-side having a small distanceto each other so that the number of photodiodes detects only reflectedinfrared radiation and not directly emitted infrared radiation. Theadjacent arrangement enables the detection of a high proportion of thereflected infrared light.

In an exemplary embodiment, the optical sensor unit may comprise anarray of a plurality of photodiodes forming an image sensor that isadapted for high speed parallel read out. In particular, the opticalsensor unit must be capable of providing sufficient resolution in orderto enable reading out the infrared readable data, in particular encodedinfrared readable data provided on the movable component. For example,the infrared readable data uses an 8-bit array and the optical sensorunit comprises an array of about 20-80 photodiodes. This number ofphotodiodes is capable to provide sufficient resolution in order toenable reading the 8-bit code information and to allow the processorunit to decode the encoded infrared readable data. The array ofphotodiodes may be assigned to one single electromagnetic radiationsource.

In an alternative exemplary embodiment, the optical sensor unit maycomprise a one-dimensional array of a few photodiodes, e.g., sixphotodiodes adjacent to each other, forming a simple light sensitivesensor. Every single photodiode may be assigned to one electromagneticradiation source for detecting if an electromagnet radiation signal isdetected or not. This configuration of the optical sensor unit may besuitable for detecting an axial position of a gauge element of the drugdelivery device which is adapted to cover a part of a window arrangedwithin the case through which a currently set or remaining dose ofmedicament is indicated.

A semiconductor material used for the photodiode depends on the spectralsensitivity of the required wavelength range. For example, silicon maybe used to produce the photodiode or photodiodes. Such siliconphotodiodes are cost-effective and comprise peak sensitivity at awavelength range of 905 nm, which is close to a peak wavelength emissionspectrum of the infrared light emitting diode.

Furthermore, the processing unit may be configured to determine aposition of the movable component relative to a case of the drugdelivery device. The determined relative position of the movablecomponent enables determining a currently selected dose of medicamentcontained within the drug delivery device. For indicating the valuedetermined by the processing unit, the reading device further comprisesa display. The reading device may also comprise a memory unit forstoring history data, whereby the history data comprises at leastinformation about dose size, injection time, injection duration and drugtype.

The disclosure further relates to a drug delivery device adapted todispense a variable dose of a medicament and to couple to a readingdevice according to the disclosure, wherein the drug delivery devicecomprises a case and a movable component, wherein the movable componentis arranged within the case and wherein the movable component is movablewith respect to the case.

The movable component is provided with infrared readable data that isassigned to visual data. The infrared readable data is represented by anumber of at least one of infrared readable symbols, signs, characters,icons, markings, codes, bars and signals.

The visual data is represented by a sequence of at least one of visualsymbols, signs, characters, icons, markings, codes, bars and signals,whereby the number of infrared readable data is assigned to the sequenceof visual data and each visual data indicates a dose of medicament.

The number of infrared readable data is arranged on a covered part ofthe movable component that is opaque to visible light.

The drug delivery device provides the visual data, in particular encodedvisual data for visibly indicating a selected or remaining dose ofmedicament wherein the infrared readable data are assigned to thesequence of visual data. The visual data can be read out by the readingdevice and may be indicated as a selected or remaining dose ofmedicament by a displayed value. Due to the covered and invisiblearrangement of the infrared readable data, the drug delivery device canbe operated without any visible interference for the user.

Furthermore, the infrared readable data and the visual data are assignedto the same data value characterizing at least one of a parameter, astate, a dose and a position of at least one of a medicament, acomponent of the drug delivery device and the drug delivery device.

In an exemplary embodiment, the number of machine or infrared readablesymbols may be represented as a number of metal areas printed on asurface of the covered part of the movable component. The infraredradiation transmitted through the case will be reflected when strikingthe metal area due to suppression of wave propagation beyond theso-called skin depth of metal. That means metal provides high contrastwith remaining plastic parts of the drug delivery device when using aninfrared light emitting diode as the electromagnetic radiation source.As a result, a signal-to-noise ratio may be substantially high. Here,the sequence of visual data, e.g. symbols may be arranged on a visiblepart of the movable component or on a dose indicator sleeve that ispartly visible through a window, e. g. an aperture that is arrangedwithin the case such that at least the visual symbol is visible throughthe window, which represents the currently selected dose of medicament.

The drug delivery device may be configured such that the covered part ofthe movable component is covered by an opaque part of the case and/or byan opaque outer surface of the movable component. Here, the infraredradiation is allowed to be transmitted through the opaque part of thecase and/or through the opaque outer surface of the movable component inorder to illuminate the covered and invisible part of the movablecomponent on which the machine readable symbols, in particular theinfrared readable symbols are arranged. This configuration enables theuser to visibly indicate the selected or remaining dose of medicamentand at the same time enabling another indication of the selected orremaining dose of medicament, e.g., by digital indication, withoutrequiring an additional window or aperture.

In an exemplary embodiment, the infrared readable data is represented bya plurality of infrared readable symbols or the like, wherein each ofthe infrared readable data is assigned to one of the visual datarespectively. For example, every visual symbol printed on the movablecomponent is represented by an infrared readable symbol. One infraredreadable data may be configured as a binary code. For this case, theoptical sensor unit may be configured as an image sensor.

The infrared readable data may be applied onto the covered part of themovable component respectively, wherein the covered part may be an innersurface that is covered by the visible part of the movable component,which is configured as an opaque layer of white colour or plastic.

Furthermore, the visual data are arranged onto the visible part of themovable component, wherein the machine readable data, in particularinfrared readable data are arranged onto the covered part of the movablecomponent in a manner that each visual data that is currently visiblethrough the window and the machine or infrared readable data assigned tothis visual data are arranged phase-shifted to each other on the movablecomponent. Thus a read-out point of the machine or infrared readabledata is phase-shifted to the visual data currently visible through thewindow. That means, the machine or infrared readable data, e.g., asymbol and the visual data, e.g., a symbol that is currently visiblethrough the window are offset to each other at a determined angle in aplane that is perpendicular to a longitudinal axis of the drug deliverydevice.

Alternatively, the infrared readable data is represented by a singlemetal area arranged on the covered part of the movable component,whereby the covered part may be configured as an outer surface that isarranged adjacent a gauge window. The gauge window is arranged withinthe movable component. The visual data is represented for example by asequence of numbers arranged on a dose indicator sleeve, whereby thedose indicator sleeve is rotatable with respect to the case and withrespect to the movable component.

Here, the movable component is configured as a sleeve-like componentthat is arranged between the case and the dose indicator sleeve, wherebythe movable component is axially movable with respect to the case andinteracts mechanically with a piston. The piston is arranged within amedicament container in a manner that the visual data, e.g. a symbolindicated through the window and/or the gauge window will be ejectedfrom the medicament container. The gauge window is arranged with respectto the window of the case such that at least a part of the doseindicator sleeve is visible through the window and the gauge window. Theposition of the gauge window may thus be used to identify the currentlyset and/or dispensed dose of medicament.

A drug delivery device in combination with a reading device may comprisea case and a movable component, whereby the movable component isarranged within the case. The movable component is furthermore movablewith respect to the case and is provided with infrared readable datathat is assigned to visual data. The reading device is adapted toread-out the infrared readable data.

The reading device comprises at least one electromagnetic radiationsource that is configured to emit electromagnetic radiation and that isadapted to illuminate the covered part of the movable component. Thereading device further comprises at least one optical sensor unit thatis configured to detect electromagnetic radiation reflected from themovable component. Moreover, the reading device comprises at least oneprocessing unit that is configured to determine a value as a function ofthe measured reflected electromagnetic radiation.

The combination of the drug delivery device and the reading deviceallows detecting information related to a state, condition, parameter,dose and/or use of the drug delivery device, such as a selected dosewithout the requirement of an additional window or aperture in the caseof the drug delivery device.

In particular, the at least one electromagnetic radiation source may beconfigured to emit infrared radiation which is allowed to transmitthrough a plastic material, which is conventionally used for the case ofthe drug delivery device.

Further scope of applicability of the present disclosure will becomeapparent from the detailed description given hereinafter. However, itshould be understood that the detailed description and specificexamples, while indicating exemplary embodiments of the disclosure, aregiven by way of illustration only, since various changes andmodifications within the spirit and scope of the disclosure will becomeapparent to those skilled in the art from this detailed description.

FIG. 1 schematically shows a cut-out of a longitudinal section of anexemplary embodiment of a drug delivery device 1 comprising a movablecomponent 1.1.

The drug delivery device 1 may be configured as a pre-filled, disposableinjection pen or as an autoinjector comprising a case 1.2 receiving themovable component 1.1 and at least a medicament container 1.5 (see FIG.10 ) to which a needle may be fixed (not illustrated). The needle may beprotected by an inner needle cap and an outer needle cap (notillustrated).

A dose of medicament to be ejected from the drug delivery device 1 canbe selected by turning a dose selector 1.3, e. g. a dial grip, in arotational direction and the selected dose is then displayed through anwindow 1.2.1 arranged within the case 1.2. The selected dose may beindicated by a sequence of visual symbols 1.1.1 that represents visualdata D_(opt). The visual symbols 1.1.1 are arranged on a visible part1.1.1.1 of the movable component 1.1, whereby the visible part 1.1.1.1is an outer circumference. Hence, the sequence of visual symbols 1.1.1may be printed or laser marked spirally around the outer circumferenceof the movable component 1.1. The visual symbols 1.1.1 may be furtherprinted as numbers, icons, bars or the like. In an exemplary embodiment,the visual symbols 1.1.1 may represent values of so-called InternationalUnits (IU), whereby one IU may be a value of 0.0347 mg of human insulin.The window 1.2.1 is a transparent part of the case 1.2 permeable forvisible light and may have dimensions enabling indicating exactly onevisual symbol 1.1.1. For example, the window 1.2.1 is configured as anaperture.

The movable component 1.1 may be configured as a sleeve-like componentforming a number sleeve movable with respect to the case 2 andmechanically interacting with a piston 1.6 (see FIG. 10 ) in themedicament container 1.5 in a manner that, when the needle is piercedinto a suited skin portion of a patient and a button 1.4 is pushed, thevisual symbol 1.1.1 that is indicated through the window 1.2.1 and thatcorresponds with the selected dose of medicament will be ejected fromthe drug delivery device 1. Here, the movable component 1.1 is caused torotate and to move axially relative to the case 1.2 when an amount ofmedicament is selected or ejected. The visual symbols 1.1.1 printed onthe movable component 1.1 successively align with the window 1.2.1 asthe movable component 1.1 moves rotationally and axially. When an amountof medicament has been selected, the visual symbol 1.1.1 correspondingto the dialled amount of medicament is visible through the window 1.2.1.When the medicament is dispensed, a rotational and axial movement of themovable component 1.1 cause the visual symbol 1.1.1, which is currentlyvisible through the window 1.2.1, to be that associated with theselected amount of medicament remaining in the drug delivery device 1yet to be dispensed.

The case 1.2 of the drug delivery device 1 may comprise support elements(not illustrated), e.g., one or more protrusions and/or one or moreindentations, which allow releasably attaching a reading device 2adapted to read out infrared readable data D associated to the selectedor remaining amount of medicament.

FIG. 2 shows a perspective view of an exemplary embodiment of a readingdevice 2 attached to the drug delivery device 1.

The reading device 2 is configured as an integral component of the drugdelivery device 1. The reading device 2 comprises a housing 2.1, whichreceives at least one electromagnetic radiation source 2.2 and at leastone optical sensor unit 2.3. Alternatively, the at least oneelectromagnetic radiation source 2.2 and at least one optical sensorunit 2.3 may be arranged on an outside of the housing 2.1.

The electromagnetic radiation source 2.2 may be configured as a lightemitting diode emitting infrared radiation (see FIG. 8 ). Infraredradiation emitting diodes are known as providing maximum intensity at awavelength of around 900 nm.

Common materials used for the case 1.2, e.g., polypropylene, have a hightransmissivity for infrared radiation but are opaque to visible lightsuch that a user cannot view through the case. Thus, the emittedinfrared radiation is allowed to be transmitted through the opaque case1.2 until hitting a reflecting component. According to the disclosure,the reflecting component is the infrared readable data D and is providedon a covered part 1.1.1.2 part of the movable component 1.1, which isarranged within the case 1.2. The infrared readable data D isrepresented by infrared readable symbols D_(ir). The infrared readablesymbols D_(ir) may be configured as a metal part, e.g., atwo-dimensional metal area M representing a binary code, whereby everyvisual symbol 1.1.1 is dedicated to one infrared readable symbolsD_(ir). Alternatively, the two-dimensional binary code is configured asa one dimensional binary code, e.g., a bar code. Further alternatively,the infrared readable data D may be represented by at least one ofinfrared readable signs, characters, icons and markings. The signs,characters, icons or markings may be optionally encoded.

Because the infrared readable symbols D_(ir) are configured as ametallized parts, the part of the movable component 1.1, on which theinfrared readable symbols D,_(ir)are arranged, provides high contrastwith remaining plastic parts of the drug delivery device 1 when using aninfrared radiation emitting diode as the electromagnetic radiationsource 2.2.

The infrared readable data D, in particular the symbols D,_(ir)may beprinted onto the covered part 1.1.1.2 of the movable component 1.1 thatmay be configured as an inner surface of an outer wall of the movablecomponent 1.1. For being invisible to a user viewing through the window1.2.1 and thus be invisible for a transparent or light permeable part ofthe case 1.2, the infrared readable symbols D_(ir) may be covered by thevisible part 1.1.1.1 of the movable component 1.1 that is configured asa thin layer of plastic or colour. For example, every visual symbol1.1.1 is printed onto a thin layer provided on the outer wall of themovable component 1.1, whereby the respective infrared readable symbolD_(ir) is provided below this layer regarding a radial inward directionand being thus invisible for a user.

The drug delivery device 1 may provide 120 doses of medicament to beejected from the drug delivery device 1. That corresponds to a coding of6.9 bits and thus approximately 7 bits and as a result a code element isrequired to comprise eight pixels at minimum (see FIG. 3 ). Due to theorderly sequence of the visual symbols 1.1.1, here printed as numbers,only the even numbers may be printed onto the movable component 1.1.This enables decreasing the coding to 5.9 bits or approximately 6 bits,respectively. Codes those are difficult to detect, such as all pixelsare filled or empty, may be omitted.

The optical sensor unit 2.3 is adapted to receive electromagneticradiation that is reflected when striking the metallized infraredreadable symbols D_(ir) due to a suppression of wave propagation beyondthe so-called skin depth of metal. In particular, metal provides highcontrast with remaining plastic parts of the drug delivery device 1 whenusing an infrared radiation emitting diode as the electromagneticradiation source 2.2. As a result a signal-to-noise ratio (SNR) may besubstantially high. Due to the binary code configuration of the infraredreadable data D, the optical sensor unit 2.3 preferably comprises anarray of a plurality of photodiodes 2.3.4 forming an image sensor thatmeasures the intensity of the electromagnetic radiation reflected fromthe binary code (see FIG. 6 ).

The electromagnetic radiation source 2.2 and the optical sensor unit 2.3are arranged adjacent to each other on the outside of the housing 2.1facing the outer circumference of the case 1.2 of the drug deliverydevice 1. In particular, the electromagnetic radiation source 2.2 andthe optical sensor unit 2.3 are arranged horizontally side-by-side witha small distance to each other such that the optical sensor unit 2.3 iscapable to detect electromagnetic radiation that is emitted by theelectromagnetic radiation source 2.2 and reflected from the covered part1.1.1.2. The optical sensor unit 2.3 may be optically isolated from theelectromagnetic radiation source 2.2 to avoid detecting (unreflected)electromagnetic radiation directly from the electromagnetic radiationsource 2.2. This may be realized by a milling groove or a metal layerbetween the electromagnetic radiation source 2.2 and the optical sensorunit 2.3. Furthermore, the electromagnetic radiation source 2.2 and/orthe optical sensor unit 2.3 may be provided with or coupled to a numberof optical elements, e.g. optical lenses, for optimizing a directiveefficiency of the emitted electromagnetic radiation and/or reflectedelectromagnetic radiation. Due to the fact that the drug delivery device1 may comprise other metal components or parts, the reading device 2 andthe drug delivery device 1 are required to be arranged to each other ina manner enabling substantially direct contact between the readingdevice 2 and the drug delivery device 1.

The combination of an infrared radiation emitting diode 2.2.5 and anarray of a plurality of photodiodes 2.3.4, e. g. each comprising siliconmaterial, could be advantageous due to the fact that infrared radiationemitting diodes 2.2.5 are powerful, economical and durable at leastuntil a wavelength range of 900 nm and that photodiodes 2.3.4 comprisingsilicon are cost-effective and comprise peak sensitivity at a wavelengthrange of 905 nm, which is close to the peak wavelength emission spectrumof the infrared radiation emitting diode 2.2.5.

Following, an exemplary configuration of the infrared readable data Dprovided on the movable component 1.1 according to FIGS. 1 and 2 will bedescribed in more detail.

FIG. 3 shows two exemplary embodiments of a pixel pattern P comprisingtwo rows of four pixels that result in a sum of eight pixels. Byreference to the so-called Nyquist-Shannon sampling theorem, at leasttwo pixels of the pixel pattern P are required to be filled with metal,thereby generating a specific binary code i, depending on which pixelsare filled.

FIG. 4 schematically shows a single visual symbol 1.1.1, here “2”, andan infrared readable symbol D_(ir) assigned to this visual symbol 1.1.1.

Generally, every digit of the visual symbols 1.1.1 is dedicated to aspecific binary code, which results in sum to a sequence of binary codesforming infrared readable symbol D_(ir), which is assigned to thespecific visual symbol 1.1.1. Here, the visual symbol 1.1.1 “2” isprinted above the infrared readable symbol D_(ir), whereby the layerbetween the visual symbol 1.1.1 and the infrared readable symbol D_(ir)is not shown.

FIG. 5 illustrates a visual symbol 1.1.1 printed as “024” and thuscomprising the digits “0”, “2”, and “4” in sequence. The digit “0” maybe associated to a binary code represented by only one filled pixel. Thedigits “2” and “4” are associated to a binary code respectivelyrepresented by two different filled pixels. The binary codes result insum to the specific infrared readable symbol D_(ir) that is associatedto the visual symbol 1.1.1 printed as “024”.

FIG. 6 shows a schematic cut out of the exemplary embodiment of the drugdelivery device 1 similar to that shown in FIGS. 1 and 2 .

The window 1.2.1 and the electromagnetic radiation source 2.2 arearranged opposite to each other in a circumferential direction, wherebythe optical sensor unit 2.3 is arranged adjacent to the electromagneticradiation source 2.2 in order to receive reflected electromagneticradiation and converting the reflected electromagnetic radiation into animage. For example, the window 1.2.1 is facing a patient and theelectromagnetic radiation source 2.2 and the optical sensor unit 2.3 arearranged on the opposite side. That means the optical sensor unit 2.3detects electromagnetic radiation reflected from an infrared readablesymbol D_(ir) that is covered by a layer on which the visual symbol1.1.1 is arranged that is currently not indicated through the window1.2.1 and being thus offset to the visual symbol 1.1.1, which iscurrently aligned with the window 1.2.1.

The visual symbol 1.1.1 that is currently visible through the window1.2.1 and the assigned infrared readable symbol D_(ir) are arrangedoffset to each other at a certain angle, e.g., at an angle of 180degrees, in a plane that is perpendicular to a longitudinal axis of thedrug delivery device 1. This must be taken into account when evaluatingthe reflected electromagnetic radiation as it is described in contextwith FIG. 10 .

FIG. 7 shows a schematic cut-out view of an alternative exemplaryembodiment of a drug delivery device 10 and a reading device 20.

The drug delivery device 10 may be configured as a pre-filled,disposable injection pen or as an autoinjector comprising a case 10.2receiving a movable component 10.1 and at least a medicament container10.5 (see FIG. 10 ) to which a needle may be fixed (not illustrated).The needle may be protected by an inner needle cap and an outer needlecap (not illustrated).

A dose of medicament to be ejected from the drug delivery device 10 canbe selected by turning a dose selector 10.3, e. g. a dial grip, in arotational direction. The dose selector 10.3 is coupled to a doseindicator sleeve 10.7 in a manner such that the dose indicator sleeve10.7 rotates together with the dose selector 10.3. The dose indicatorsleeve 10.7 is provided with visual data D_(10opt), which is representedby a sequence of visual symbols 10.7.1. The visual symbols 10.7.1.areprinted or laser marked spirally around a part 10.7.2 of the doseindicator sleeve 10.7, wherein the part 10.7.2 of the dose indicatorsleeve 10.7 is an outer circumference of the dose indicator sleeve 10.7.

According to the present embodiment, the movable component 10.1 isconfigured as a gauge element that may have the shape of a shield or astrip extending in a longitudinal direction of the drug delivery device10. As an alternative, the movable component 10.1 may be a sleeve.

The movable component 10.1 is arranged between the case 10.2 and thedose indicator sleeve 10.7 and is partly visible through a window 10.2.1arranged within the case 10.2. The window 10.2.1 is a transparent orlight permeable part of the case 10.2 that may have larger dimensionsthan the window 1.2.1 illustrated in FIG. 1 . In particular, the window1.2.1 extends in a longitudinal direction enabling to indicate alongitudinal portion of the dose indicator sleeve 10.7.

For indicating the currently set or remaining dose of medicament, themovable component 10.1 comprises a gauge window 10.1.2 that is arrangedwith respect to the window 10.2.1 such that a part of the dose indicatorsleeve 10.7, in particular the currently set or remaining dose ofmedicament, is visible through the window 10.2.1 and the gauge window10.1.2. In other words, the movable component 10.1 may be used to shieldor cover a portion of the dose indicator sleeve 10.7 and to allowviewing only on a limited portion of the dose indicator sleeve 10.7 thatindicates the currently set and/or dispensed dose of medicament.

To facilitate this, the dose indicator sleeve 10.7 and the movablecomponent 10.1 may be in a threaded engagement such that the movablecomponent 10.1 is axially displaced with respect to the case 10.2 andthe dose indicator sleeve 10.7 upon rotation of the dose indicatorsleeve 10.7. That means, as the dose selector 10.3 is dialled, the doseindicators sleeve 10.7 rotates correspondingly and the movable component10.1 moves axially along the outer circumference of the dose indicatorsleeve 10.7.

Furthermore, the movable component 10.1 is provided with infraredreadable data D₁₀ that may be represented by an infrared readable symbolD_(10ir), which is configured as a metal area M10 printed on a coveredpart 10.1.1.2 of the movable component 10.1, wherein the covered part10.1.1.2 is an outer section of the movable component 10.1 that iscovered by an opaque part of the case 10.2. The infrared readable dataD₁₀ is used to detect an axial position of the movable component 10.1with respect to the dose indicator sleeve 10.7 in order to determine thecurrently set or remaining dose of medicament, which is visiblyindicated through the gauge window 10.1.2. According to the presentembodiment, the infrared readable symbol D_(10ir) is arranged on a sideof the movable component that is opposite to the gauge window 10.1.2 ina circumferential direction.

The detection of the axial position of the movable component 10.1 withrespect to the dose indicator sleeve 10.7 is carried out by the readingdevice 20.

The reading device 20 is a supplemental component to the drug deliverydevice 10. In particular, the reading device 20 may be configured to beattached to the drug delivery device 10, for example releasably oralternatively irreleasably. Alternatively, the reading device 20 isconfigured as a remote component.

The reading device 20 may optionally comprise a transmitter 21 totransmit the data and/or the data value as read from the drug deliverydevice 10 to another device 30, e.g. transmit the data wirelessly, forexample via radio, to a mobile phone or a walk-by device or a remoteterminal.

The reading device 20 comprises an array of six electromagneticradiation sources 20.2 and six corresponding photodiodes 20.3.4 formingthe optical sensor unit 20.3. The optical sensor unit 20.3 is configuredto detect an axial position of the infrared readable symbol D_(10ir)that is provided on the covered part 10.1.1.2 of the movable component10.1.

The number of electromagnetic radiation sources 20.2 and correspondingphotodiodes 20.3.4 is exemplarily used because it may be required torecognize only six different axial positions of the movable component10.1 in order to evaluate the currently set or remaining dose ofmedicament. For example, this may be due to a total amount of possibledoses of medicament of 120 International Units that are helicallydistributed about the outer circumference of the dose indicator sleeve10.7 over five turns. The number of electromagnetic radiation sources20.2 and corresponding photodiodes 20.3.4 is thus suitable to detect thefive turns in the longitudinal direction.

The reading device 20 may be coupled to the drug delivery device 10 byconnecting a housing 20.1 of the reading device 20 with the case 10.2 ofthe drug delivery device 10, e.g., by one or more protrusions and/or oneor more indentations as mentioned above. In particular, the readingdevice 20 may be coupled adjacent to the window 10.2.1 in order not tocover the window 10.2.1 and the gauge window 10.1.2, thereby facing anangular portion of the movable component 10.1 that comprises the coveredpart 10.1.1.2 on which the infrared readable symbol D_(10ir) isarranged.

Furthermore, the reading device 20 may be coupled to the drug deliverydevice 10 such that the array of six electromagnetic radiation sources20.2 and six corresponding photodiodes 20.3.4 extends along an axis thatis substantially parallel to the axis along which the movable component10.1 is configured to move. A longitudinal extension of the readingdevice 20 may be nearly similar to a longitudinal extension of thewindow 10.2.1. In particular, one end-side electromagnetic radiationsource 20.2 is located above one end of the window 10.2.1 at which thegauge window 10.1.2 is located when the minimum dose is set. An oppositeend-side electromagnetic radiation source 20.2 is located above theother end of the window 10.2.1 at which the gauge window 10.1.2 islocated when the maximum dose is set.

The case 10.2 and the movable component 10.1 may be illuminated by theelectromagnetic radiation sources 20.2 by successively generating shortand high current pulses through the electromagnetic radiation sources20.2, which may emit low-frequency infrared radiation. This enables tosuccessively query signal responses of the photodiodes 20.3.4, wherebyone of the photodiodes 20.3.4 detects reflected infrared radiation whenthe emitted infrared radiation strikes the metal area M10 on the movablecomponent 10.1. By means of predetermined angular position informationof the electromagnetic radiation sources 2.2 and/or the correspondingphotodiodes 20.3.4 with respect to the gauge window 10.1.2., an absolutevalue of the currently set dose indicated through the gauge window10.1.2 can be evaluated.

FIG. 8 shows a circuit diagram of a single electromagnetic radiationsource 20.2 of the reading device 20 according to the exemplaryembodiment illustrated in FIG. 7 . The electromagnetic radiation source20.2 is configured as an electromagnetic radiation emitting diode20.2.5. The circuit diagram shows a power source 20.2.1, e.g., a currentsource, a diode 20.2.2, a resistor 20.2.3 and a transistor 20.2.4. Thetransistor 20.2.4 is connected to the diode 20.2.2, which is coupled tothe power source 20.2.1 in a forward conducting direction. The resistor20.2.3 is arranged between the diode 20.2.2 and the transistor 20.2.4.

The power source 20.2.1 provides short but high current pulses for apowerful and efficiency operation of the electromagnetic radiationsource 20.2.

FIG. 9 shows a circuit diagram of a single photodiode 20.3.4 of anoptical sensor unit 20.3 according to the exemplary embodimentillustrated in FIG. 7 .

The circuit diagram shows a further diode 20.3.1, e.g., anelectromagnetic radiation sensitive photodiode, coupled to a comparator20.3.2 that is coupled with a further resistor 20.3.3 in turn.

As mentioned above, the optical sensor unit 20.3 is adapted to receivereflected infrared light. The intensity of the reflected infrared lightdepends on the configuration of the metal area and thus on the specificbinary code. For decoding the data D₁₀ by analysing the reflectedelectromagnetic radiation detected from the further diode 20.3.1, theoptical sensor unit 20.3 is coupled to a processing unit 20.4 asillustrated in FIG. 10 .

FIG. 10 is a block diagram of the reading device 2, 20 and the drugdelivery device 1, 10. The reading device 2, 20 comprises the housing2.1, 20.1, the electromagnetic radiation source 2.2 or electromagneticradiation sources 20.2, the optical sensor unit 2.3, 20.3, theprocessing unit 2.4, 20.4, a memory unit 2.5, 20.5 and a display unit2.6, 20.6.

The processing unit 2.4, 20.4 may be configured as a microprocessorreceived within the housing 2.1, 20.1. The processing unit 2.4, 20.4 iscoupled to the optical sensor unit 2.3, 20.3 for decoding the infraredreadable data D, D₁₀ in order to evaluate which dose is currentlyselected. Because the reading device 2, 20 is arranged such that thewindow 1.2.1, 10.2.1 is not covered, the optical sensor unit 2.3, 20.3receives electromagnetic radiation reflected from the infrared readablesymbols D_(ir), D_(10ir) that is located offset to the window 1.2.1,10.2.1, 10.1.2 ata certain angle, e. g. at an angle of 180 degrees. Thedetail information regarding a position of the electromagnetic radiationsource 2.2 or the electromagnetic radiation sources 20.2 with respect tothe window 1.2.1, 10.2.1 may be saved in the processing unit 2.4, 20.4.

Referring to the exemplary embodiment of the drug delivery device 10illustrated in FIG. 7 , the electromagnetic radiation sources 20.2 willbe subjected to short and high current pulses, whereby one of thephotodiodes of the optical sensor unit 20.3 detects reflectedelectromagnetic radiation. This has the advantage that other disturbingeffects, e. g.

extraneous electromagnetic radiation, will be faded. Furthermore, theevaluation of the currently set or remaining dose of medicamentindicated through the gauge window 10.1.2 may be performed in an easymanner, e.g., by thresholding (image processing).

Alternatively, the optical sensor unit 20.3 may be analysed by use of aconstant pulse period, e.g., by pulse width modulation of the reflectedelectromagnetic radiation signal at 50% or by pulse width modulation ofthe electromagnetic radiation signal emitted by the electromagneticradiation sources 20.2.

In further alternative embodiments, the processing unit 20.4 may beprovided with or coupled to a so-called lock-in amplifier comprising amultiplier or to a pseudo-random signal generator. The latter includesdetecting reflected electromagnetic radiation by the optical sensor unit20.3 over a measurement period having several light-dark phases that maybe integrated over the measurement period, thereby forming an irregularsequence such that a Fourier-transformed frequency spectrum includes aplurality of different frequencies. Each individual frequency makes onlya small contribution to the measurement result. This allows for a highsignal-to-noise ratio.

By starting or activating the reading device 20, the row ofelectromagnetic radiation sources 20.2 will be successively queried asit is described already in context with FIG. 7 . It is required todetect exactly one reflected electromagnetic radiation signal. If noreflected electromagnetic radiation signal or more than one reflectedelectromagnetic radiation signals are detected, an error has occurred.At the beginning of a dose selection performance, the reflectedelectromagnetic radiation signal is detected by a predetermined firstphotodiode of the optical sensor unit 20.3. Otherwise, the drug deliverydevice 10 is not set to zero. For this purpose, the reading device 10 iscalibrated to a predetermined standard signal.

During dose selection, the reflected signal changes, i.e., the doseindicator sleeve 10.7, rotates and the movable component 10.1 movesaxially with respect to the dose indicator sleeve 10.7. It may be thenconcluded that the visual symbol 10.7.1 that is currently indicatedthrough the gauge window 10.2.1 has changed. Current positions of themovable component 10.1 relative to the reading device 20 are clearlyidentifiable, because intermediate areas between the photodiodes 20.3.4supply two signals smaller than one signal of a center area.

If no more changes occur, it can be assumed that dose setting isfinished. Then the evaluated value of the dialled dose will be saved.When the patient starts an injection process, the movable component 1.1rotates in the other direction or the movable component 10.1 moves inthe other axial direction and the visual symbols 1.1.1, 10.7.1, i.e.,the set dose, count to zero. If the current dose comprises the value“0”, thereby assuming that injection had really occurred, the value ofthe dose set before may be saved in the memory unit 2.5, 20.5.Preferably, the memory unit 2.5, 20.5 is configured to store a pluralityof history values. The current and/or history values may be visuallyindicated via the display unit 2.6, 20.6. Alternatively or additionally,the current and/or history values may be acoustically indicated.

The terms “drug” or “medicament” are used herein to describe one or morepharmaceutically active compounds. As described below, a drug ormedicament can include at least one small or large molecule, orcombinations thereof, in various types of formulations, for thetreatment of one or more diseases. Exemplary pharmaceutically activecompounds may include small molecules; polypeptides, peptides andproteins (e.g., hormones, growth factors, antibodies, antibodyfragments, and enzymes); carbohydrates and polysaccharides; and nucleicacids, double or single stranded DNA (including naked and cDNA), RNA,antisense nucleic acids such as antisense DNA and RNA, small interferingRNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids maybe incorporated into molecular delivery systems such as vectors,plasmids, or liposomes. Mixtures of one or more of these drugs are alsocontemplated.

The term “drug delivery device” shall encompass any type of device orsystem configured to dispense a drug into a human or animal body.Without limitation, a drug delivery device may be an injection device(e.g., syringe, pen injector, auto injector, large-volume device, pump,perfusion system, or other device configured for intraocular,subcutaneous, intramuscular, or intravascular delivery), skin patch(e.g., osmotic, chemical, micro-needle), inhaler (e.g., nasal orpulmonary), implantable (e.g., coated stent, capsule), or feedingsystems for the gastro-intestinal tract. The presently described drugsmay be particularly useful with injection devices that include a needle,e.g., a small gauge needle.

The drug or medicament may be contained in a primary package or “drugcontainer” adapted for use with a drug delivery device. The drugcontainer may be, e.g., a cartridge, syringe, reservoir, or other vesselconfigured to provide a suitable chamber for storage (e.g., short- orlong-term storage) of one or more pharmaceutically active compounds. Forexample, in some instances, the chamber may be designed to store a drugfor at least one day (e.g., 1 to at least 30 days). In some instances,the chamber may be designed to store a drug for about 1 month to about 2years. Storage may occur at room temperature (e.g., about 20° C.), orrefrigerated temperatures (e.g., from about −4° C. to about 4° C.). Insome instances, the drug container may be or may include a dual-chambercartridge configured to store two or more components of a drugformulation (e.g., a drug and a diluent, or two different types ofdrugs) separately, one in each chamber. In such instances, the twochambers of the dual-chamber cartridge may be configured to allow mixingbetween the two or more components of the drug or medicament prior toand/or during dispensing into the human or animal body. For example, thetwo chambers may be configured such that they are in fluid communicationwith each other (e.g., by way of a conduit between the two chambers) andallow mixing of the two components when desired by a user prior todispensing. Alternatively or in addition, the two chambers may beconfigured to allow mixing as the components are being dispensed intothe human or animal body.

The drug delivery devices and drugs described herein can be used for thetreatment and/or prophylaxis of many different types of disorders.Exemplary disorders include, e.g., diabetes mellitus or complicationsassociated with diabetes mellitus such as diabetic retinopathy,thromboembolism disorders such as deep vein or pulmonarythromboembolism. Further exemplary disorders are acute coronary syndrome(ACS), angina, myocardial infarction, cancer, macular degeneration,inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis.

Exemplary drugs for the treatment and/or prophylaxis of diabetesmellitus or complications associated with diabetes mellitus include aninsulin, e.g., human insulin, or a human insulin analogue or derivative,a glucagon-like peptide (GLP-1), GLP-1 analogues or GLP-1 receptoragonists, or an analogue or derivative thereof, a dipeptidyl peptidase-4(DPP4) inhibitor, or a pharmaceutically acceptable salt or solvatethereof, or any mixture thereof. As used herein, the term “derivative”refers to any substance which is sufficiently structurally similar tothe original substance so as to have substantially similar functionalityor activity (e.g., therapeutic effectiveness).

Exemplary insulin analogues are Gly(A21), Arg(B31), Arg(B32) humaninsulin (insulin glargine); Lys(B3), Glu(B29) human insulin; Lys(B28),Pro(B29) human insulin; Asp(B28) human insulin; human insulin, whereinproline in position B28 is replaced by Asp, Lys, Leu, Val or Ala andwherein in position B29 Lys may be replaced by Pro; Ala(B26) humaninsulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30)human insulin.

Exemplary insulin derivatives are, for example, B29-N-myristoyl-des(B30)human insulin; B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoylhuman insulin; B29-N-palmitoyl human insulin; B28-N-myristoylLysB28ProB29 human insulin; B28-N-palmitoyl-LysB28ProB29 human insulin;B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N-palmitoyl-ThrB29LysB30human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) humaninsulin; B29-N-(N-lithocholyl-gamma-glutamyl)-des(B30) human insulin;B29-N-(ω-carboxyheptadecanoyl)-des(B30) human insulin andB29-N-(ω-carboxyheptadecanoyl) human insulin. Exemplary GLP-1, GLP-1analogues and GLP-1 receptor agonists are, for example:Lixisenatide/AVE0010/ZP10/Lyxumia, Exenatide/Exendin-4/Byetta/Bydureon/ITCA 650/AC-2993 (a 39 amino acid peptide which is produced bythe salivary glands of the Gila monster), Liraglutide/Victoza,Semaglutide, Taspoglutide, Syncria/Albiglutide, Dulaglutide, rExendin-4,CJC-1134-PC, PB-1023, TTP-054, Langlenatide/HM-11260C, CM-3, GLP-1Eligen, ORMD-0901, NN-9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1,CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929,ZP-3022, TT-401, BHM-034. MOD-6030, CAM-2036, DA-15864, ARI-2651,ARI-2255, Exenatide-XTEN and Glucagon-Xten. An exemplary oligonucleotideis, for example: mipomersen/Kynamro, a cholesterol-reducing antisensetherapeutic for the treatment of familial hypercholesterolemia.

Exemplary DPP4 inhibitors are Vildagliptin, Sitagliptin, Denagliptin,Saxagliptin, Berberine.

Exemplary hormones include hypophysis hormones or hypothalamus hormonesor regulatory active peptides and their antagonists, such asGonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin),Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin,Triptorelin, Leuprorelin, Buserelin, Nafarelin, and Goserelin.

Exemplary polysaccharides include a glucosaminoglycane, a hyaluronicacid, a heparin, a low molecular weight heparin or an ultra-lowmolecular weight heparin or a derivative thereof, or a sulphatedpolysaccharide, e.g. a poly-sulphated form of the above-mentionedpolysaccharides, and/or a pharmaceutically acceptable salt thereof. Anexample of a pharmaceutically acceptable salt of a poly-sulphated lowmolecular weight heparin is enoxaparin sodium. An example of ahyaluronic acid derivative is Hylan G-F 20/Synvisc, a sodiumhyaluronate.

The term “antibody”, as used herein, refers to an immunoglobulinmolecule or an antigen-binding portion thereof. Examples ofantigen-binding portions of immunoglobulin molecules include F(ab) andF(ab′)₂ fragments, which retain the ability to bind antigen. Theantibody can be polyclonal, monoclonal, recombinant, chimeric,de-immunized or humanized, fully human, non-human, (e.g., murine), orsingle chain antibody. In some embodiments, the antibody has effectorfunction and can fix complement. In some embodiments, the antibody hasreduced or no ability to bind an Fc receptor. For example, the antibodycan be an isotype or subtype, an antibody fragment or mutant, which doesnot support binding to an Fc receptor, e.g., it has a mutagenized ordeleted Fc receptor binding region.

The terms “fragment” or “antibody fragment” refer to a polypeptidederived from an antibody polypeptide molecule (e.g., an antibody heavyand/or light chain polypeptide) that does not comprise a full-lengthantibody polypeptide, but that still comprises at least a portion of afull-length antibody polypeptide that is capable of binding to anantigen. Antibody fragments can comprise a cleaved portion of a fulllength antibody polypeptide, although the term is not limited to suchcleaved fragments. Antibody fragments that are useful in the presentdisclosure include, for example, Fab fragments, F(ab′)₂ fragments, scFv(single-chain Fv) fragments, linear antibodies, monospecific ormultispecific antibody fragments such as bispecific, trispecific, andmultispecific antibodies (e.g., diabodies, triabodies, tetrabodies),minibodies, chelating recombinant antibodies, tribodies or bibodies,intrabodies, nanobodies, small modular immunopharmaceuticals (SMIP),binding-domain immunoglobulin fusion proteins, camelized antibodies, andVHH containing antibodies. Additional examples of antigen-bindingantibody fragments are known in the art.

The terms “Complementarity-determining region” or “CDR” refer to shortpolypeptide sequences within the variable region of both heavy and lightchain polypeptides that are primarily responsible for mediating specificantigen recognition. The term “framework region” refers to amino acidsequences within the variable region of both heavy and light chainpolypeptides that are not CDR sequences, and are primarily responsiblefor maintaining correct positioning of the CDR sequences to permitantigen binding. Although the framework regions themselves typically donot directly participate in antigen binding, as is known in the art,certain residues within the framework regions of certain antibodies candirectly participate in antigen binding or can affect the ability of oneor more amino acids in CDRs to interact with antigen.

Exemplary antibodies are anti PCSK-9 mAb (e.g., Alirocumab), anti IL-6mAb (e.g., Sarilumab), and anti IL-4 mAb (e.g., Dupilumab).

The compounds described herein may be used in pharmaceuticalformulations comprising (a) the compound(s) or pharmaceuticallyacceptable salts thereof, and (b) a pharmaceutically acceptable carrier.The compounds may also be used in pharmaceutical formulations thatinclude one or more other active pharmaceutical ingredients or inpharmaceutical formulations in which the present compound or apharmaceutically acceptable salt thereof is the only active ingredient.Accordingly, the pharmaceutical formulations of the present disclosureencompass any formulation made by admixing a compound described hereinand a pharmaceutically acceptable carrier.

Pharmaceutically acceptable salts of any drug described herein are alsocontemplated for use in drug delivery devices. Pharmaceuticallyacceptable salts are for example acid addition salts and basic salts.Acid addition salts are e.g. HCl or HBr salts. Basic salts are e.g.salts having a cation selected from an alkali or alkaline earth metal,e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), whereinR1 to R4 independently of each other mean: hydrogen, an optionallysubstituted C1-C6-alkyl group, an optionally substituted C2-C6-alkenylgroup, an optionally substituted C6-C10-aryl group, or an optionallysubstituted C6-C10-heteroaryl group. Further examples ofpharmaceutically acceptable salts are known to those of skill in thearts.

Pharmaceutically acceptable solvates are for example hydrates oralkanolates such as methanolates or ethanolates.

Those of skill in the art will understand that modifications (additionsand/or removals) of various components of the substances, formulations,apparatuses, methods, systems and embodiments described herein may bemade without departing from the full scope and spirit of the presentdisclosure, which encompass such modifications and any and allequivalents thereof.

LIST OF REFERENCES

1, 10 drug delivery device

1.1, 10.1 movable component

1.1.1 visual symbol

1.1.1.1 visible part

1.1.1.2 covered part

10.1.1.2 covered part

10.1.2 gauge window

1.2, 10.2 case

1.2.1, 10.2.1 window

1.3, 10.3 dose selector

1.4, 10.4 button

1.5, 10.5 medicament container

1.6, 10.6 piston

10.7 dose indicator sleeve

10.7.1 visual symbol

10.7.2 visible part

2, 20 reading device

2.1, 20.1 housing

2.2, 20.2 electromagnetic radiation source

20.2.1 power source

20.2.2 diode

20.2.3 resistor

20.2.4 transistor

2.2.5, 20.2.5 electromagnetic radiation emitting diode

2.3, 20.3 optical sensor unit

20.3.1 diode

20.3.2 comparator

20.3.3 resistor

2.3.4, 20.3.4 photodiode

2.4, 20.4 processing unit

2.5, 20.5 memory unit

2.6, 20.6 display unit

21 transmitter

30 device

D, D₁₀ infrared readable data

D_(ir), D_(10ir) infrared readable symbol

D_(opt), D_(10opt) visual data

M, M10 metal area

P pixel pattern

1. (canceled)
 2. A reading device adapted to read a first type of dataprovided on a first portion of a movable component of a drug deliverydevice, wherein the first type of data comprises information regardingthe drug delivery device, the reading device comprising: at least oneemitting unit configured to emit a signal capable of recording a firsttype of data; at least one sensor configured to detect the signal withthe recorded first type of data obtained from the first portion of themovable component; and at least one processing unit configured todetermine a first data value for the information from the first type ofdata detected by the sensor.
 3. The reading device of claim 2, whereinthe signal is an infrared radiation and the first type of data comprisesinfrared readable representations of data.
 4. The reading device ofclaim 3, wherein the infrared readable representations of data areencoded as respective binary codes.
 5. The reading device of claim 2wherein the information comprises information regarding a state, acondition, a parameter, a dose, and/or a use of the drug deliverydevice, wherein the dose of the drug delivery device comprises aselected dose for injection.
 6. The reading device of claim 2, furthercomprising a transmitter to transmit the read first type of data and/orthe determined first data value to another device wirelessly.
 7. Thereading device of claim 2, wherein the reading device is configured tobe connected or to be connectable to the drug delivery device to havedirect contact with the drug delivery device.
 8. The reading device ofclaim 2 wherein the read first type of data is used to detect an axialposition of the movable component with respect to a dose indicatorsleeve of the drug delivery device.
 9. The reading device of claim 2,wherein the at least one sensor comprises a number of photodiodes. 10.The reading device of claim 2, wherein the processing unit is coupled tothe at least one sensor for decoding the read first type of data toevaluate the information and/or extract the information from the firsttype of data.
 11. The reading device of claim 2, wherein a secondportion of the movable component comprises a second type of data. 12.The reading device of claim 11, wherein the first portion of the movablecomponent and the second portion of the movable component are offset toeach other at a determined angle in a plane that is perpendicular to alongitudinal axis of the drug delivery device.
 13. The reading device ofclaim 11, wherein the second type of data is provided on a visiblesecond portion of the movable component.
 14. The reading device of claim11, wherein the first type of data and the second type of data aredifferent types of data.
 15. The reading device of claim 11, wherein theinformation determined from the first type of data and informationdetermined from the second type of data correspond to each other. 16.The reading device of claim 11, wherein the second type of data includevisual representations of data.
 17. The reading device of claim 16wherein the visual representations of data are represented by a sequenceof at least one of visual symbols, signs, characters, icons, markings,codes, bars, or signals.
 18. The reading device of claim 11 furtheradapted to read the second type of data and determine a second datavalue for the information from the second type of data.
 19. A drugdelivery device comprises: a case; a movable component arranged withinthe case, wherein the movable component is movable with respect to thecase, wherein the movable component is provided with a first type ofdata that is assigned to a second type of data, the first type of databeing provided on a first portion of the movable component and thesecond type of data being provided on a second portion of the moveablecomponent; and a reading device adapted to read the first type of data,wherein the reading device comprises: at least one emitting unitconfigured to emit a signal capable of recording the first type of data;at least one sensor configured to detect the signal with the recordedfirst type of data obtained from the first portion of the movablecomponent; and at least one processing unit configured to determine afirst data value for information from the first type of data detected bythe sensor.
 20. The drug delivery device of claim 19, wherein the firsttype of data comprise infrared readable representations of data and thesecond type of data comprise visual representations of data.
 21. Thedrug delivery device of claim 19, wherein the reading device is adaptedto read-out the second type of data.